Literature DB >> 26003026

The 24-Month Prognosis of Patients With Positive or Intermediate Results in the Intracoronary Ergonovine Provocation Test.

Dong Il Shin1, Sang Hong Baek2, Sung Ho Her3, Seung Hwan Han4, Youngkeun Ahn5, Keun-Ho Park5, Dong-Soo Kim6, Tae-Hyun Yang6, Dong-Ju Choi7, Jung-Won Suh7, Hyuck Moon Kwon8, Byoung Kwon Lee8, Hyeon-Cheol Gwon9, Seung-Woon Rha10, Sang-Ho Jo11.   

Abstract

OBJECTIVES: This study was an observational, multicenter registry to determine clinical characteristics and 24-month prognosis of patients who underwent intracoronary ergonovine provocation tests.
BACKGROUND: The clinical characteristics and prognosis of patients who underwent the ergonovine provocation for vasospastic angina were not fully elucidated.
METHODS: A total of 2,129 patients in the VA-KOREA (Vasospastic Angina in Korea) registry were classified into positive (n = 454), intermediate (n = 982), and negative (n = 693) groups by intracoronary ergonovine provocation tests. The 24-month incidences of cardiac death, new-onset arrhythmia, and acute coronary syndrome were determined (mean 26.7 ± 8.8 months).
RESULTS: The number of smokers, frequency of angina before angiography, high-sensitivity C-reactive protein, and triglyceride were higher in the positive group than in other groups. The clinical characteristics of the intermediate and the negative groups were very similar. In the positive group, the incidences of diffuse, focal, and mixed spasm were 65.9%, 23.6%, and 10.6%. Coronary spasm was more frequently provoked on atherosclerotic segments. The 24-month incidences of cardiac death, arrhythmia, and acute coronary syndrome were low (0.9%, 1.6%, and 1.9%, respectively) in the positive group, and there was no cardiac death in the intermediate group (p = 0.02). In the positive group, frequent angina, current smoking, and multivessel spasm were independent predictors for adverse events.
CONCLUSIONS: The 24-month prognosis of the positive group in the intracoronary ergonovine provocation test was relatively worse than that of the intermediate group. More intensive clinical attention should be paid to vasospastic angina patients with high-risk factors including frequent angina before angiography, current smoking, and multivessel spasm.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ergonovine; prognosis; vasospastic angina

Mesh:

Substances:

Year:  2015        PMID: 26003026     DOI: 10.1016/j.jcin.2014.12.249

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  17 in total

1.  Effect of intracoronary adenosine on ergonovine-induced vasoconstricted coronary arteries.

Authors:  Jun-Hyok Oh; Seunghwan Song; Changhoon Kim; Jinhee Ahn; Jin Sup Park; Hye Won Lee; Jung Hyun Choi; Han Cheol Lee; Kwang Soo Cha; Taek Jong Hong
Journal:  Cardiol J       Date:  2018-07-16       Impact factor: 2.737

2.  Admission serum potassium levels and prognosis of vasospastic angina.

Authors:  Won-Woo Seo; Sang-Ho Jo; Sung Eun Kim; Hyun-Jin Kim; Seung Hwan Han; Kwan Yong Lee; Sung Ho Her; Min-Ho Lee; Seong-Sik Cho; Hack-Lyoung Kim; Sang Hong Baek
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

3.  Clinical Outcomes of Vasospastic Angina Patients Presenting With Acute Coronary Syndrome.

Authors:  Sung Woo Cho; Taek Kyu Park; Hye Bin Gwag; A Young Lim; Min Seok Oh; Da Hyon Lee; Choong Sil Seong; Jeong Hoon Yang; Young Bin Song; Joo-Yong Hahn; Jin-Ho Choi; Sang Hoon Lee; Hyeon-Cheol Gwon; Seung-Hyuk Choi
Journal:  J Am Heart Assoc       Date:  2016-11-16       Impact factor: 5.501

Review 4.  Coronary artery spasm: Current knowledge and residual uncertainties.

Authors:  Massimo Slavich; Riyaz Suleman Patel
Journal:  Int J Cardiol Heart Vasc       Date:  2016-01-23

5.  Incidence and factors associated with mortality in 2,476 patients with variant angina in Korea.

Authors:  Hack-Lyoung Kim; Jayeun Kim; Hyun Joo Kim; Woo-Hyun Lim; Jin Yong Lee
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

6.  Subcutaneous implantable cardioverter-defibrillator implantation for ventricular fibrillation caused by coronary artery spasm: a case report.

Authors:  Naruhiko Ito; Manabu Kurabayashi; Kaoru Okishige; Kenzo Hirao
Journal:  Eur Heart J Case Rep       Date:  2018-07-03

7.  Coronary Computed Tomography Angiography for the Diagnosis of Vasospastic Angina: Comparison with Invasive Coronary Angiography and Ergonovine Provocation Test.

Authors:  Hyung Kwan Kim; Eun Ah Park; Jiesuck Park; Jun Bean Park; Seung Pyo Lee; Whal Lee; Yong Jin Kim; Dae Won Sohn
Journal:  Korean J Radiol       Date:  2019-05       Impact factor: 3.500

8.  Prognosis and Predictors of Mortality in Patients Suffering Myocardial Infarction With Non-Obstructive Coronary Arteries.

Authors:  Eun Ho Choo; Kiyuk Chang; Kwan Yong Lee; Dongjae Lee; Jae Gyung Kim; Youngkeun Ahn; Young Jo Kim; Shung Chull Chae; Myeong Chan Cho; Chong Jin Kim; Hyo-Soo Kim; Myung Ho Jeong
Journal:  J Am Heart Assoc       Date:  2019-07-09       Impact factor: 5.501

9.  Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study.

Authors:  Taek-Geun Kwon; Albert Youngwoo Jang; Sang Wook Kim; Young Joon Hong; Jang-Ho Bae; Sung Yun Lee; Sang-Hyun Kim; Seung Hwan Han
Journal:  Trials       Date:  2020-04-22       Impact factor: 2.279

10.  Guidelines for reasonable and appropriate care in the emergency department (GRACE): Recurrent, low-risk chest pain in the emergency department.

Authors:  Paul I Musey; Fernanda Bellolio; Suneel Upadhye; Anna Marie Chang; Deborah B Diercks; Michael Gottlieb; Erik P Hess; Michael C Kontos; Bryn E Mumma; Marc A Probst; John H Stahl; Jason P Stopyra; Jeffrey A Kline; Christopher R Carpenter
Journal:  Acad Emerg Med       Date:  2021-07-06       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.